You are here

Article info

Article menu

Download PDFPDF

XML
Case report
Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab

Authors

  • Jamie S Lin Section of Nephrology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Daniel Y Wang Section of Hematology-Oncology, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Omar Mamlouk Section of Nephrology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • William F Glass Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Maen Abdelrahim Department of Medical Oncology, Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Cassian Yee Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articlesGoogle scholar articles
  • Ala Abudayyeh Section of Nephrology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ala Abudayyeh; aabudayyeh{at}mdanderson.org
View Full Text

Citation

Lin JS, Wang DY, Mamlouk O, et al
Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
Journal for ImmunoTherapy of Cancer 2020;8:e001287. doi: 10.1136/jitc-2020-001287

Publication history

  • Accepted August 27, 2020
  • First published October 5, 2020.
Online issue publication 
October 05, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.